Pharmidex provides both in vitro and preclinical solutions in the treatment of autoimmune diseases such as multiple sclerosis, psoriasis, atopic dermatitis, alopecia and vitiligo.



Our extensive expertise in this field can combine proof of concept studies with pharmacokinetic, pharmacodynamics, toxicological and bioanalytical endpoints to help fast track your research programmes.

Areas of Expertise

Alopecia

Cyclophosphamide, cisplatin, fluorouracil

• Various species 
• Maximum study duration: 2 months
• Routes of administration: Topical, oral, intraperitoneal and subcutaneous

Psoriasis

Atopic Dermatitis

Haptens, OVA and HDM model

• Various species
• Maximum study duration: 3 months.
• Routes of administration: Topical, oral, intraperitoneal, intravenous and subcutaneous
  

Vitiligo

Monobenzene

• Single species
• Maximum study duration: 13 weeks
• Routes of administration: Topical

Multiple Sclerosis (EAE)

MOG35-55 peptide and proteolipid protein

• Various species
• Maximum study duration: 3 months
• Drug treatment observation period: 40 days. 
• Routes of Administration: Oral, intraperitoneal, intranasal, intravenous, intrathecal and subcutaneous